A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

NCT04275518 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions

DRUG: APG-115
DRUG: Azacitidine
DRUG: Cytarabine

Sponsor

Ascentage Pharma Group Inc.

Collaborators

[object Object]